AU2016334290B2 - Antibody to hepatitis B surface antigen and use thereof - Google Patents

Antibody to hepatitis B surface antigen and use thereof Download PDF

Info

Publication number
AU2016334290B2
AU2016334290B2 AU2016334290A AU2016334290A AU2016334290B2 AU 2016334290 B2 AU2016334290 B2 AU 2016334290B2 AU 2016334290 A AU2016334290 A AU 2016334290A AU 2016334290 A AU2016334290 A AU 2016334290A AU 2016334290 B2 AU2016334290 B2 AU 2016334290B2
Authority
AU
Australia
Prior art keywords
seq
set forth
antibody
antigen binding
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016334290A
Other languages
English (en)
Other versions
AU2016334290A1 (en
Inventor
Wenxin Luo
Ningshao Xia
Quan Yuan
Juan Zhang
Jun Zhang
Tianying ZHANG
Bing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yang Sheng Tang Co Ltd
Xiamen University
Original Assignee
Yang Sheng Tang Co Ltd
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd, Xiamen University filed Critical Yang Sheng Tang Co Ltd
Publication of AU2016334290A1 publication Critical patent/AU2016334290A1/en
Application granted granted Critical
Publication of AU2016334290B2 publication Critical patent/AU2016334290B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2016334290A 2015-10-09 2016-10-09 Antibody to hepatitis B surface antigen and use thereof Active AU2016334290B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510647977 2015-10-09
CN201510647977.7 2015-10-09
PCT/CN2016/101560 WO2017059813A1 (zh) 2015-10-09 2016-10-09 抗乙肝表面抗原的抗体及其用途

Publications (2)

Publication Number Publication Date
AU2016334290A1 AU2016334290A1 (en) 2018-05-10
AU2016334290B2 true AU2016334290B2 (en) 2020-06-18

Family

ID=58487306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016334290A Active AU2016334290B2 (en) 2015-10-09 2016-10-09 Antibody to hepatitis B surface antigen and use thereof

Country Status (10)

Country Link
US (1) US10689434B2 (enExample)
EP (1) EP3360896B1 (enExample)
JP (2) JP6949012B2 (enExample)
KR (1) KR102132604B1 (enExample)
CN (1) CN106565840B (enExample)
AU (1) AU2016334290B2 (enExample)
BR (1) BR112018007121A2 (enExample)
CA (1) CA3001231C (enExample)
ES (1) ES3041684T3 (enExample)
WO (1) WO2017059813A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689434B2 (en) * 2015-10-09 2020-06-23 Xiamen University Antibody against hepatitis B surface antigen and use thereof
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
CA3099900A1 (en) * 2018-05-31 2019-12-05 Daiichi Sankyo Company, Limited Anti-human tlr7 antibody
WO2020130138A1 (ja) * 2018-12-21 2020-06-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
AU2020280543B2 (en) * 2019-05-23 2025-08-28 Xiamen University Anti-hepatitis B virus antibodies and use thereof
CN111242107B (zh) * 2020-04-26 2021-03-09 北京外号信息技术有限公司 用于设置空间中的虚拟对象的方法和电子设备
WO2024148263A1 (en) * 2023-01-06 2024-07-11 Victorian Infectious Diseases Reference Laboratory Methods and compositions for antibody treatment of hepatitis b infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786592A (zh) * 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
CN102906111A (zh) * 2009-12-24 2013-01-30 株式会社绿十字 特异性结合乙型肝炎病毒表面抗原的人抗体
WO2015107126A1 (en) * 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517636A (ja) 2000-10-02 2004-06-17 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
WO2009093263A1 (en) * 2008-01-23 2009-07-30 Department Of Biotechnology A humanized high affinity recombinant antibody against hepatitis b surface antigen
WO2013185558A1 (zh) 2012-06-11 2013-12-19 厦门大学 用于治疗hbv感染及相关疾病的多肽及抗体
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
US10689434B2 (en) * 2015-10-09 2020-06-23 Xiamen University Antibody against hepatitis B surface antigen and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102906111A (zh) * 2009-12-24 2013-01-30 株式会社绿十字 特异性结合乙型肝炎病毒表面抗原的人抗体
CN102786592A (zh) * 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
WO2015107126A1 (en) * 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

Also Published As

Publication number Publication date
JP2018533937A (ja) 2018-11-22
US10689434B2 (en) 2020-06-23
EP3360896A4 (en) 2019-08-28
WO2017059813A1 (zh) 2017-04-13
KR20180084045A (ko) 2018-07-24
BR112018007121A2 (pt) 2018-11-06
JP2021063092A (ja) 2021-04-22
JP6949012B2 (ja) 2021-10-13
CA3001231C (en) 2022-07-12
CN106565840A (zh) 2017-04-19
CA3001231A1 (en) 2017-04-13
EP3360896B1 (en) 2025-07-23
KR102132604B1 (ko) 2020-07-13
CN106565840B (zh) 2020-09-01
ES3041684T3 (en) 2025-11-13
US20190389939A1 (en) 2019-12-26
EP3360896A1 (en) 2018-08-15
AU2016334290A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
AU2016334290B2 (en) Antibody to hepatitis B surface antigen and use thereof
JP2019518459A (ja) Ｌａｇ−３抗体、その抗原結合フラグメント、およびそれらの医薬的用途
IL296800A (en) Neutralizing antibodies to the polyoma virus
US20250368722A1 (en) Multispecific antibodies targeting multiple epitopes on the hiv-1 envelope
JP2024112879A (ja) Ｂ型肝炎抗体
RU2765878C2 (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
US20230272048A1 (en) Hiv-1 antibodies
JP2022507599A (ja) 安定性が向上した抗ｃ－ｍｅｔ抗体又はその抗原結合断片
AU2022292722B2 (en) Anti-csp antibodies
CN113549146A (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途
CN115197323A (zh) 一种sn38抗体或其抗原结合片段及其应用
WO2024088342A1 (en) Antibodies against cd24 and uses thereof
RU2841957C1 (ru) Сконструированные антитела против il-2
WO2024123897A1 (en) Broadly neutralizing and potent antibodies against hiv
JP2025094941A (ja) Ｌａｇ－３アゴニスト抗体
OA21630A (en) Anti-CSP antibodies.
CN117480183A (zh) 抗il-36r抗体及其用途
HK40059983A (en) Polyomavirus neutralizing antibodies
HK40079597A (en) Antibodies binding il4r and uses thereof
HK40079597B (zh) 结合il4r的抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)